4//SEC Filing
Lappe Mark 4
Accession 0001739614-24-000037
CIK 0002007919other
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 5:31 PM ET
Size
13.5 KB
Accession
0001739614-24-000037
Insider Transaction Report
Form 4
Lappe Mark
DirectorChief Executive Officer
Transactions
- Purchase
Common Stock
2024-08-30$14.02/sh+10,000$140,200→ 145,000 total(indirect: By Trust) - Purchase
Common Stock
2024-09-03$16.31/sh+4,712$76,853→ 165,000 total(indirect: By Trust) - Purchase
Common Stock
2024-09-03$15.66/sh+15,288$239,410→ 160,288 total(indirect: By Trust) - Purchase
Common Stock
2024-08-29$14.03/sh+10,000$140,300→ 135,000 total(indirect: By Trust)
Holdings
- 621,548(indirect: By Trust)
Common Stock
- 54,865(indirect: By IRA)
Common Stock
Footnotes (6)
- [F1]The shares were purchased in multiple transactions at prices ranging from $13.9079 to $14.245, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F2]These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.
- [F3]The shares were purchased in multiple transactions at prices ranging from $13.96 to $14.13, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F4]The shares were purchased in multiple transactions at prices ranging from $15.115 to $16.11, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F5]The shares were purchased in multiple transactions at prices ranging from $16.115 to $16.465, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- [F6]These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.
Documents
Issuer
Inhibrx Biosciences, Inc.
CIK 0002007919
Entity typeother
Related Parties
1- filerCIK 0001366074
Filing Metadata
- Form type
- 4
- Filed
- Sep 2, 8:00 PM ET
- Accepted
- Sep 3, 5:31 PM ET
- Size
- 13.5 KB